Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Zometa

Known as: Novartis brand of zoledronic acid 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Aging skeletal muscle is associated with not only a reduction in muscle size and strength but also in muscle quality which… Expand
Highly Cited
2011
Highly Cited
2011
OBJECTIVE Bisphosphonates (BPs) like Zometa (ZA) are widely used to treat complications of bony metastases in cancer patients. A… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2009
2009
Drs. Lisa Schwartz and Steven Woloshin write that much critical information that the FDA has at the time of approval may fail to… Expand
Highly Cited
2007
Highly Cited
2007
PURPOSE Treatment with aromatase inhibitors decreases bone mineral density (BMD) and may increase the risk of fractures in… Expand
Highly Cited
2006
Highly Cited
2006
Objectives: To identify synergistic combinations of clinically available agents with zoledronic acid which would enhance… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2003
Highly Cited
2003
BACKGROUND Renal failure and toxic acute tubular necrosis (ATN) may be seen following exposure to a variety of therapeutic agents… Expand
Highly Cited
2002
Highly Cited
2002
Bisphosphonates (BPs) are pyrophosphate analogues in which the oxygen in P-O-P has been replaced by a carbon, resulting in a… Expand
Review
2002
Review
2002
Bisphosphonates are the treatment of choice for lytic bone lesions associated with breast cancer. In contrast, bone lesions… Expand
Review
2001
Review
2001
The propensity for breast cancer cells to metastasize to bone and to induce osteolysis has long been recognized. Characteristics… Expand
2000
2000
Metastatic bone disease develops as a result of the many interactions between tumour cells and bone cells. This leads to… Expand